| Management of treatment-related toxicity with targeted therapies for renal cell carcinoma: evidence-based practice and best practices. | |
| | |
MedLine Citation:
|
PMID: 21763973 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
The advent of targeted agents for the treatment of advanced renal cell carcinoma has led to dramatic improvements in therapy. However, the chronic use of these medications has also led to the identification of new toxicities that require long-term management. Effective management of toxicity is needed to maximize the benefits of treatment and improve patients' quality of life. In addition, toxicity from these agents may affect treatment compliance, particularly with daily oral agents. This review delineates the toxicities that require monitoring, the underlying pathophysiology (when known), and treatments that may have benefits in relieving symptoms and side effects. |
| | |
Authors:
|
Laurie Appleby; Stephanie Morrissey; Joaquim Bellmunt; Jonathan Rosenberg |
Related Documents
:
|
14583243 - Solid waste management in indian himalayan tourists' treks: a case study in and around ... 21475053 - Introducing hcm v3.0: a standard model for hospital case management practice. 10945193 - Use of misoprostol in obstetrics and gynecology. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Hematology/oncology clinics of North America Volume: 25 ISSN: 1558-1977 ISO Abbreviation: Hematol. Oncol. Clin. North Am. Publication Date: 2011 Aug |
Date Detail:
|
Created Date: 2011-07-18 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8709473 Medline TA: Hematol Oncol Clin North Am Country: United States |
Other Details:
|
Languages: eng Pagination: 893-915 Citation Subset: IM |
Copyright Information:
|
Copyright © 2011 Elsevier Inc. All rights reserved. |
Affiliation:
|
The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, D1230, Boston, MA 02215, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far.
Next Document: Future directions in renal cell carcinoma: 2011 and beyond.